Daraxonrasib has received breakthrough therapy designation from the FDA for KRAS G12+, previously treated, metastatic pancreatic ductal adenocarcinoma.

More than 90% of patients living with PDAC have tumors carrying a RAS cancer driver mutation with ~85% carrying a KRAS G12 mutation. Revolution Medicines is currently enrolling patients in ...

The first session of play belonged to Sri Lanka skipper Charith Asalanka who cracked a century for his side to make a modest 244 and in the second sesion spin duo ...

Clinical Research and Trials Studies involving patients that investigate the efficacy of novel screening strategies, therapeutics, combinations, or regimens in the setting of clinical investigation ...